Endo settled off-label charges for $192 million, resolving civil "whistleblower" suits filed by two sales reps and a physician.
The FDA commissioner said the agency is doing its job, not picking a fight, when it inspects drug-making facilities, and that India must take an active role for a harmonious supply chain.
The drugmaker revealed efficacy data that analysts say could prompt the health agencies to emphasize adult vaccination.
Gaming does not trivialize the patient's experience of a chronic disease
Success cures fear, and success is born out of focus and hard work
FDA's Warning Letter to Aegerion is a bureaucratic thumb in the eye to the US Court of Appeals
Endo is restructuring, bringing its four operating units under the same corporate roof and rebranding to reflect its diversification out of its origins in pain and urology drugs.